Search Result

Results for "

butyrylcholinesterase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (2) Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (18) Apoptosis (5) Bacterial (1) Beta-secretase (6) Calcium Channel (1) Cannabinoid Receptor (2) Carbonic Anhydrase (3) Caspase (1) CCR (1) Cholinesterase (ChE) (125) Complement System (1) COX (1) Cytochrome P450 (2) Drug Derivative (8) Drug Intermediate (1) Endogenous Metabolite (3) Epoxide Hydrolase (3) FAAH (1) FAP (1) Fluorescent Dye (1) Fungal (1) Glycosidase (3) GSK-3 (3) HDAC (1) Histamine Receptor (3) Histone Acetyltransferase (2) HSP (1) IKK (2) Insecticide (1) Interleukin Related (4) Isotope-Labeled Compounds (4) JNK (4) Keap1-Nrf2 (1) mAChR (1) MMP (1) Monoamine Oxidase (12) Necroptosis (1) NF-κB (5) NO Synthase (1) NOD-like Receptor (NLR) (5) p38 MAPK (3) Parasite (1) Potassium Channel (2) Reactive Oxygen Species (ROS) (5) Reference Standards (5) ROS Kinase (2) SOD (1) Tau Protein (5) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) TRP Channel (2) γ-secretase (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (14) Metabolic Disease (10) Neurological Disease (128)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (2)

Aldehyde Dehydrogenase (ALDH) (1)

Amyloid-β (18)

Apoptosis (5)

Bacterial (1)

Beta-secretase (6)

Calcium Channel (1)

Cannabinoid Receptor (2)

Carbonic Anhydrase (3)

Caspase (1)

CCR (1)

Cholinesterase (ChE) (125)

Complement System (1)

COX (1)

Cytochrome P450 (2)

Drug Derivative (8)

Drug Intermediate (1)

Endogenous Metabolite (3)

Epoxide Hydrolase (3)

FAAH (1)

FAP (1)

Fluorescent Dye (1)

Fungal (1)

Glycosidase (3)

GSK-3 (3)

HDAC (1)

Histamine Receptor (3)

Histone Acetyltransferase (2)

HSP (1)

IKK (2)

Insecticide (1)

Interleukin Related (4)

Isotope-Labeled Compounds (4)

JNK (4)

Keap1-Nrf2 (1)

mAChR (1)

MMP (1)

Monoamine Oxidase (12)

Necroptosis (1)

NF-κB (5)

NO Synthase (1)

NOD-like Receptor (NLR) (5)

p38 MAPK (3)

Parasite (1)

Potassium Channel (2)

Reactive Oxygen Species (ROS) (5)

Reference Standards (5)

ROS Kinase (2)

SOD (1)

Tau Protein (5)

TGF-beta/Smad (1)

TGF-β Receptor (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

TRP Channel (2)

γ-secretase (1)

By Research Areas:

Cancer (17)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (14)

Metabolic Disease (10)

Neurological Disease (128)

152

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Garcinol 5 Publications Verification	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards *acetyl cholinesterase* (AChE)** and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 μM and 7.39 μM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

Rivastigmine 1 Publications Verification ENA 713 free base; SDZ-ENA 713 free base	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Rivastigmine tartrate 1 Publications Verification ENA 713; SDZ-ENA 713	Cholinesterase (ChE)	Neurological Disease
Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Iso-OMPA Tetraisopropyl pyrophosphoramide	Cholinesterase (ChE)	Neurological Disease
Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

Butyrylcholinesterase (BCHE), Horse Serum BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl	Others	Others
Butyrylcholinesterase (BCHE), Horse Serum (BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl) is a biological material or organic compound that can be used in life science research .

Gypsogenin	Cholinesterase (ChE) Apoptosis Necroptosis	Neurological Disease Cancer
Gypsogenin is a selective mixed-type BChE inhibitor (K_i=19.99 μM) that also exhibits significant cytotoxicity against various human cancer cell lines. Gypsogenin inhibits tumor growth by inducing cell cycle arrest and triggering apoptosis. Gypsogenin displays antibacterial activity against bacteria such as Bacillus subtilis and Bacillus thuringiensis, and often serves as a key parent nucleus for the synthesis of anticancer compounds. Gypsogenin is widely used in research on Alzheimer's disease and various cancers including colon cancer, melanoma, and leukemia .

8-Deoxygartanin	Parasite NF-κB	Infection
8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of butyrylcholinesterase (BChE) . 8-Deoxygartanin exhibits antiplasmodial activity with an IC₅₀ of 11.8 μM for the W2 strain of Plasmodium falciparum . 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC₅₀ of 11.3 μM .

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

Rivastigmine (Standard) ENA 713 free base(Standard); SDZ-ENA 713 free base(Standard)	Reference Standards Cholinesterase (ChE)	Neurological Disease
Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

BChE-IN-11	Cholinesterase (ChE)	Neurological Disease
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

Iso-OMPA (Standard) Tetraisopropyl pyrophosphoramide (Standard)	Cholinesterase (ChE) Reference Standards	Neurological Disease
Iso-OMPA (Standard) is the analytical standard of Iso-OMPA. This product is intended for research and analytical applications. Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

Desoxypeganine Deoxypeganine; Deoxyvasicine	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC₅₀ values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research .

Isograndifoliol	Cholinesterase (ChE)	Cardiovascular Disease Neurological Disease Cancer
Isograndifoliol is a selective inhibitor of *butyrylcholinesterase* (BChE) with an IC₅₀ value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC₅₀ value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .

Echothiopate iodide Echothiophate iodide	Cholinesterase (ChE)	Neurological Disease
Echothiopate iodide is a potent hBChE (human butyrylcholinesterase) inhibitor. Echothiopate iodide is a long-acting anticholinesterase agent. Echothiopate iodide can be used for glaucoma research .

BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-1 (Compound 23) is a potent inhibitor of butyrylcholinesterase (BuChE). Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer’s disease (AD). BuChE-IN-1 shows low cytotoxicity and high blood brain barrier (BBB) permeability. BuChE-IN-1 is a promising BuChE inhibitor for the research of AD .

BChE-IN-28	Cholinesterase (ChE)	Neurological Disease
BChE-IN-28 (compound 6J) is a selective butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 8 nM and a K_i of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B .

Mirabegron impurity-1	Adrenergic Receptor	Metabolic Disease
Mirabegron impurity-1 is a potent and selective β3- adrenergic receptor agonist. Mirabegron impurity-1 has the activity of inhibiting metabolism. Mirabegron impurity-1 can be used in the study of the study of bladder impurity .

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

Kuwanon U	Cholinesterase (ChE)	Neurological Disease
Kuwanon U is a potent *cholinesterase* inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

BuChE-IN-TM-10 TM-10	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-TM-10 (TM-10) is a potent butyrylcholinesterase (BuChE) inhibitor, with an IC₅₀ of 8.9 nM. BuChE inhibitor 1 inhibits and disaggregates self-induced Aβ aggregation, exhibiting potent antioxidant activity and good blood-brain barrier (BBB) penetration. Has potential to treat Alzheimer’s disease .

AP2238	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with K_i values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease .

BChE/hCA II-IN-1	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC₅₀s of 76.50 and 10.69  μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research .

Octahydroaminoacridine	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine can be used for Alzheimer's disease (AD) research .

Octahydroaminoacridine succinate	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research .

Blestrin D	Cholinesterase (ChE)	Neurological Disease
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

BChE-IN-10	Cholinesterase (ChE)	Neurological Disease
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

BChE-IN-12	Cholinesterase (ChE)	Neurological Disease
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

hBChE-IN-2	Cholinesterase (ChE) Cannabinoid Receptor	Neurological Disease
hBChE-IN-2 (compound 15d) is a butyrylcholinesterase (BChE) inhibitor (IC₅₀ of 0.62 μM) and a cannabinoid receptor 2 (CB2R) agonist. hBChE-IN-2 has neuroprotection activities .

AChE/BChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and *Butyrylcholinesterase, with IC₅₀s of 1.06 and 7.3 nM for hAChE* and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .

BuChE-IN-6	Cholinesterase (ChE) Amyloid-β	Neurological Disease
BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation .

RX 67668	Cholinesterase (ChE)	Neurological Disease
RX 67668 is a potent *cholinesterase* inhibitor with an IC₅₀ of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. RX 67668 can reverse the neuromuscular blockade induced by D-tubocurarine. RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue .

BChE-IN-33	Cholinesterase (ChE) Cytochrome P450	Neurological Disease
BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, CYP2C9, CYP2D6. BChE-IN-33 shows potent antioxidant activity with IC₅₀ values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research .

BuChE-IN-20	Cholinesterase (ChE) Amyloid-β Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease .

AChE-IN-14	Cholinesterase (ChE) Histamine Receptor	Neurological Disease
AChE-IN-14 (compound 5) is a potent cholinesterase inhibitor with IC₅₀s of 0.46 , 0.48, and 0.44 μM for electric eel acetylcholinesterase (eeAChE), human recombinant acetylcholinesterase (hAChE), and equine serum butyrylcholinesterase (eqBuChE), respectively. AChE-IN-14 exhibits high affinity toward human H₃ receptor (H₃R; K_i= 159.8 nM). AChE-IN-14 can be used for the research of Alzheimer’s disease .

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

Rivastigmine-d3 hydrochloride ENA 713-d3 hydrochloride; SDZ-ENA 713-d3 hydrochloride	Cholinesterase (ChE) Isotope-Labeled Compounds	Neurological Disease
Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

TRV-7019	Cholinesterase (ChE)	Neurological Disease Cancer
TRV-7019 is a BBB-penetrable radioligand for brain imaging that target *butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase* activity .

AChE/BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-1 (Compound 1), a chrysin derivative, is a selective butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 0.48 μM. AChE/BuChE-IN-1 inhibits acetylcholinesterase (AChE) with an IC₅₀ of 7.16 μM. AChE/BuChE-IN-1 shows strong scavenging ·OH activities with a IC₅₀ of 0.1674 μM. AChE/BuChE-IN-1 inhibits reactive oxygen species (ROS), Aβ_1-42 aggregation (self-, Cu₂₊-induced, AChE-induced). AChE/BuChE-IN-1 has high BBB permeability and bioavailability and low cell toxicity. AChE/BuChE-IN-1 has the potential for Alzheimer' disease (AD) research .

Mirabegron impurity-1 (Standard)	Adrenergic Receptor Reference Standards	Metabolic Disease
Mirabegron impurity-1 (Standard) is the analytical standard of Mirabegron impurity-1. This product is intended for research and analytical applications. Mirabegron impurity-1 is a potent and selective β3- adrenergic receptor agonist. Mirabegron impurity-1 has the activity of inhibiting metabolism. Mirabegron impurity-1 can be used in the study of the study of bladder impurity .

Bisnorcymserine N1,N8-Bisnorcymserine; (-)-Bisnorcymserine	Cholinesterase (ChE)	Neurological Disease
Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for *butyrylcholinesterase* (BChE) with an IC₅₀ of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate .

Z32439948	Cholinesterase (ChE)	Neurological Disease
Z32439948 is a butyrylcholinesterase (BChE) inhibitor (IC₅₀: 1.4 μM, hBChE) and is a derivative of m-sulfamoylbenzamide. Z32439948 also exhibited neuroprotective effects against glutamate in SH-SY5Y cells .

BChE-IN-34	Cholinesterase (ChE)	Neurological Disease
BChE-IN-34 is a potent and selective butyrylcholinesterase (BChE) inhibitor with an IIC₅₀ of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects .

Drofenine Cycloadiphene; Hexahydroadiphenine	Potassium Channel Cholinesterase (ChE) TRP Channel NOD-like Receptor (NLR) Amyloid-β Tau Protein JNK NF-κB IKK	Neurological Disease Metabolic Disease Inflammation/Immunology
Drofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC₅₀ of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with K_i of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm .

BChE-IN-9	Cholinesterase (ChE)	Neurological Disease
BChE-IN-9 (Azepano-11-deoxo-glycyrrhetol) is a mixed type BChE inhibitor with a K_i of 0.21 µM .

Cat. No.	상품명	Type

HY-103373

PE154	Fluorescent Dyes
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and *butyrylcholinesterase* (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

HY-D3171

AD-BChE/HClO	Fluorescent Dyes
AD-BChE/HClO is a dual-target two-photon fluorescent probe. AD-BChE/HClO produces strong fluorescence only in the simultaneous presence of BChE and HClO. AD-BChE/HClO enables two-photon imaging in nerve cells and mouse brain tissues via tail vein injection. AD-BChE/HClO can be used for the research of Alzheimer's disease (Ex/Em = 450 nm/500 nm) .

Cat. No.	상품명	Target	Research Area

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

Cat. No.	상품명	Target	Research Area	Image

HY-P992076

Anti-Candida auris β-1, 3 glucans Antibody (2G8)	TGF-β Receptor TGF-beta/Smad Cholinesterase (ChE) Fungal	Infection Cancer
Anti-Candida auris β-1,3-glucans Antibody (2G8) is an antibody targeting Candida auris β-1,3-glucans, and also acts as an inhibitor of AChE and TGF-β receptor 2. Anti-Candida auris β-1,3-glucans Antibody (2G8) also targets fungal cell wall components, effectively inhibits fungal growth and interferes with capsule formation, thereby significantly reducing the fungal load in mouse tissues. Anti-Candida auris β-1,3-glucans Antibody (2G8) not only blocks TGF-β receptor binding to inhibit the Smad signaling pathway, reduces fibroblast activation and collagen deposition, but also induces epithelial differentiation of tumor cells and reduces pancreatic tumor metastasis. Anti-Candida auris β-1,3-glucans Antibody (2G8) specifically binds to the conserved N-linked glycoepitope on AChE to inhibit its activity without interfering with BChE, and can be used in studies of cryptococcosis and related tumor mechanisms .The isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P72859

	Butyrylcholinesterase/BCHE Protein, Mouse (HEK293, His) Cholinesterase; Acylcholine acylhydrolase; Choline esterase II; BCHE	Mouse	HEK293
	Butyrylcholinesterase (BCHE) Protein, an esterase with broad substrate specificity, crucially inactivates acetylcholine, maintaining neurotransmitter homeostasis. Beyond acetylcholine metabolism, BCHE degrades neurotoxic organophosphates, highlighting its detoxification role. The enzyme's versatility underscores its critical function in safeguarding against harmful effects of neurotoxic compounds. Butyrylcholinesterase/BCHE Protein, Mouse (HEK293, His) is the recombinant mouse-derived Butyrylcholinesterase/BCHE protein, expressed by HEK293 , with C-His labeled tag.

HY-P7690

	Butyrylcholinesterase/BCHE Protein, Human (HEK293, His) rHuBCHE, His; Butyrylcholine Esterase; BCHE; Choline Esterase II	Human	HEK293
	Butyrylcholinesterase/BCHE Protein, Human (HEK293, His) is a recombinant human butyrylcholinesterase (BuChE) produced in HEK293 cells, with His tag. BuChE, one of cholinesterases, is a serine hydrolase closely related to acetylcholinesterase.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명	Chemical Structure

HY-17368S2

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S1

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654335

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654336

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P82715

	Butyrylcholinesterase Antibody (YA2460) BCHE; Butyrylcholine esterase; CHE1; CHE2; Choline esterase II; Cholinesterase (serum) 2; Cholinesterase 1; Cholinesterase; E1	WB	Human
	Butyrylcholinesterase Antibody (YA2460) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Butyrylcholinesterase.